Evidence map›Paper›PMID 41913550›Full record

ArticleAnnals of medicine2026

Omission of clinical target volume in radiotherapy for unresectable stage III non-small cell lung cancer: a propensity score matching analysis.

Wenxin Ding, Jing Liang, Chaoying Chen, Jingsheng Zhao, Chaojiu Xu, Jinhua Zhang, Hao Zhou, Honghua Wu, Jian Long, Quan Zuo and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wenxin DingDepartment of Oncology, People's Hospital of Xiangxi Tujia and Miao Autonomous Prefecture, First Affiliated Hospital of Jishou University, Jishou, China.
Jing LiangDepartment of Oncology, People's Hospital of Xiangxi Tujia and Miao Autonomous Prefecture, First Affiliated Hospital of Jishou University, Jishou, China.
Chaoying ChenDepartment of Oncology, People's Hospital of Xiangxi Tujia and Miao Autonomous Prefecture, First Affiliated Hospital of Jishou University, Jishou, China.
Jingsheng ZhaoDepartment of Oncology, People's Hospital of Xiangxi Tujia and Miao Autonomous Prefecture, First Affiliated Hospital of Jishou University, Jishou, China.
Chaojiu XuDepartment of Oncology, People's Hospital of Xiangxi Tujia and Miao Autonomous Prefecture, First Affiliated Hospital of Jishou University, Jishou, China.
Jinhua ZhangDepartment of Oncology, People's Hospital of Xiangxi Tujia and Miao Autonomous Prefecture, First Affiliated Hospital of Jishou University, Jishou, China.
Hao ZhouDepartment of Oncology, People's Hospital of Xiangxi Tujia and Miao Autonomous Prefecture, First Affiliated Hospital of Jishou University, Jishou, China.
Honghua WuDepartment of Oncology, People's Hospital of Xiangxi Tujia and Miao Autonomous Prefecture, First Affiliated Hospital of Jishou University, Jishou, China.
Jian LongDepartment of Oncology, People's Hospital of Xiangxi Tujia and Miao Autonomous Prefecture, First Affiliated Hospital of Jishou University, Jishou, China.
Quan ZuoDepartment of Oncology, People's Hospital of Xiangxi Tujia and Miao Autonomous Prefecture, First Affiliated Hospital of Jishou University, Jishou, China.
Zhi YangDepartment of Oncology, People's Hospital of Xiangxi Tujia and Miao Autonomous Prefecture, First Affiliated Hospital of Jishou University, Jishou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the efficacy and adverse reactions of radiotherapy with omitted clinical target volume (CTV) in unresectable stage III non-small cell lung cancer (NSCLC).

methodsA total of 423 NSCLC patients admitted to our hospital from June 2020 to April 2024 were enrolled. Among them, 112 patients met the inclusion criteria, including 58 patients in the experimental group and 54 patients in the control group. After 1:1 propensity score matching (PSM), 66 patients were included in the final analysis, with 33 patients in each group. All patients received radical radiotherapy and were divided into experimental and control groups based on whether CTV was omitted. The efficacy and adverse reactions between the two groups were analyzed.

resultsThe objective response rates were 45.4% in the experimental group and 57.5% in the control group (

conclusionIn this cohort study of patients with unresectable stage III non-small cell lung carcinoma (NSCLC) undergoing radiation therapy, no statistically significant difference in survival was observed with omission of the CTV. However, omitting the CTV could reduce the incidence of grade ≥2 radiation pneumonitis, thereby alleviating the adverse reactions associated with this condition.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAgedFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingProgression-Free SurvivalPropensity ScoreRadiation PneumonitisRetrospective StudiesTreatment OutcomeCTV omissionnon-small cell lung cancerradiotherapystage IIIUnresectable

Identifiers

PMID41913550
PMCPMC13040567

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.